Imaging tests in staging and surveillance of non-metastatic breast cancer: changes in routine clinical practice and cost implications
Sabino De Placido, Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Carmine De Angelis(Baylor College of Medicine), Simona Cammarota(Health Economics and Outcomes Research (United Kingdom)), Grazia Arpino(University of Naples Federico II), Valentina Perrone(Unknown), G Tommasielli, Mario Giuliano(Regione Campania), C. Pizzi, Dario Bruzzese(University of Naples Federico II), Raffaella Ruocco(University of Naples Federico II)
Cited by 16
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
|Endocrine Reviews|2008|545
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
|Cancer Research|2013|485
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials
|Journal of Clinical Oncology|2007|413